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immune responses and promote tumor progression (Nishikawa and
Sakaguchi, 2014). Therapeutic utility of attenuating Treg cell function
is one of the most exciting developments in the current ﬁeld of tumor
immunology. Temporary release from the suppressive inﬂuence of
Treg cells provides beneﬁcial traits to support anti-tumor responses.
However, most therapeutic trials can only partially deplete Treg cells
or modulate Treg cell function indirectly (Pardoll, 2012). The work pre-
sented in this issue of EBioMedicine by Wang et al. (2016) provides a
new immunotherapy strategy against tumors by targeting Usp7,
which successfully dampens the immune suppressive function of Treg
cells and limits tumor growth.
The immunosuppressive phenotype of Treg cells is largely deter-
mined by the gene expression patterns driven by Foxp3 (Fontenot
et al., 2005). Ample evidence has supported that, in addition to tran-
scriptional control of the Foxp3 gene, the stability of Foxp3 expression
is also determined at the post-translational level (Chen et al., 2013;
van Loosdregt et al., 2013). Speciﬁcally, modiﬁcation of Foxp3 protein
by deubiquitination carried out by deubiquitinase Usp7 could stabilize
Foxp3 protein, effectively strengthening Treg cell function (van
Loosdregt et al., 2013). Meanwhile, the histone acetyltransferase Tip60
also plays a dominant role in promoting acetylation, dimerization and
function of Foxp3 in Treg cells (Li et al., 2007; Xiao et al., 2014). There-
fore, these pathways of post-translational Foxp3 regulation signiﬁcantly
impact the in vitro and in vivo function of Treg cells.
The work by LiqingWang et al. starts with genetic evidence that de-
velopmental deletion of Usp7 in Treg cells induces lethal systemic auto-
immunity. Usp7 depletion perturbs Treg signature gene expression,
including the Foxp3 co-regulators Eos and Gata1, and dampens the
suppressive activity of Treg cells. Usp7−/− Treg cells also acquire the ex-
pression of glycolytic genes and proliferate actively. More interestingly,DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.10.018.
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type. All these data suggest that inhibition of Usp7 might impair Treg
cell function and potentially promote anti-tumor immunity. Therefore,
pharmacologic blockade of Usp7 might provide therapeutic clues to-
wards the effective immunotherapy against cancer.
Interestingly, Treg cells abrogated their suppressive activity after
pre-treatment with Usp7 inhibitor (Usp7i) P5091 or its derivative
P0217564, which is accompanied by dramatic loss of Tip60. These ob-
servations were consistent with previous studies that Tip60 critically
regulates the function of Treg cells through promoting acetylation, di-
merization and function of Foxp3.Meanwhile, Usp7i treatment promot-
ed the ubiquitination of both Foxp3 and Tip60, and also inhibited the
formation of Foxp3 dimers. However, the expression level of Foxp3 pro-
tein was comparable inWT and Usp7−/− Treg cells, which suggests the
existence of a redundant role of Usp7 in stabilizing Foxp3 protein.
Therefore, pharmacologic inhibition of Usp7 impairs Treg cell function,
likely through mechanisms that are Tip60-dependent rather than sim-
ply via Foxp3 ubiquitination.
The therapeutic application of Usp7i in severalmouse tumormodels
shows promise, especially the combination of Usp7i with other anti-
tumor therapies. Usp7i treatment decreased the intratumoral accumu-
lation of Foxp3+ Treg cells and signiﬁcantly inhibited tumor growth.
More importantly, Usp7i treatment promoted the accumulation of
IFN-γ-producing tumor-antigen speciﬁc CD8+ T cells in the tumor mi-
croenvironment, which greatly contributed to the temporal release of
immune tolerance. Therefore, from a translational perspective, Usp7i-
mediated Treg cell inhibition shows potential as a novel approach in
the immunotherapy against tumor.
The fact that Usp7 has multiple substrates could be one of themajor
concerns in clinical trials of Usp7 inhibitors (Nicholson and Suresh
Kumar, 2011). Another problem could be the wide expression of Usp7
in many cell types. Therefore, Usp7 inhibitors might affect other cell
populations rather than simply inhibit the function of Treg cells through
Tip60 in vivo. Another preclinical study showed that Usp7i directly in-
duced apoptosis inmultiplemyeloma cells (Chauhan et al., 2012). How-
ever, from the proposed molecular mechanism in the current study by
Wang et al., Usp7i compounds can have dominant effects on Foxp3+
Tregs over that of other immune cell types, including host effector T
cells and CD8+ T cells. Therefore, pharmacologic modulation of Treg-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tolerance in the tumor microenvironment.
In summary, the data by Wang and colleagues proposes a potential
immunotherapy against tumors by targeting Usp7, which impairs Treg
cell function and subsequently breaks the immune tolerance in the
tumor microenvironment. Therefore, these preclinical ﬁndings suggest
that Usp7 targeting immunotherapy to selectively diminish Treg cell
function, as well as to directly induce tumor cell apoptosis, could have
practical signiﬁcance in clinical applications.
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